NeuroVision Imaging has acquired Durin Life Sciences, combining Durin’s blood-based biomarker diagnostics platform with NeuroVision’s retinal imaging technology, telehealth infrastructure, and BrainHealth.net patient engagement platform to create an integrated neurodegenerative disease diagnostics and care company.
Durin developed Duritect, a suite of blood-based diagnostic tests designed to support early detection and monitoring of Alzheimer’s disease, Parkinson’s disease, ALS, and related neurological disorders – in some cases years before symptoms appear. NeuroVision brings telehealth-enabled cognitive assessment, care navigation, and longitudinal brain health programs.
“We’ve long believed that the future of neurodegenerative disease care begins with earlier and more accessible detection,” said NeuroVision CEO Steven Verdooner. “By bringing together complementary strengths in diagnostics, technology and patient engagement, we believe we are uniquely positioned to help advance brain health at scale while supporting patients and families throughout the care journey.”
The combined company will continue to operate under the NeuroVision name. Ric Edelman, majority owner of Durin, joins the board.
While not positioned as a women’s health company, the Alzheimer’s connection is significant for this audience: Nearly two-thirds of Americans living with Alzheimer’s are women, and emerging research suggests the disease may not simply be a function of women living longer but may involve sex-specific biological risk factors. Earlier detection tools that reach patients before symptoms appear could disproportionately benefit the population most affected.
